利巴韦林在儿科临床应用的安全性评价

发布时间：2018-06-21 09:17

  本文选题：利巴韦林 + 儿科　； 参考：《国际药学研究杂志》2016年04期

【摘要】：利巴韦林为人工合成的核苷类抗病毒药,体外具有抑制呼吸道合胞病毒、流感病毒、甲型肝炎病毒、腺病毒等多种病毒生长的作用,其机制不全清楚。本文通过检索万方医学网、中国医院数字图书馆、医知网、中美两国食品药品监督管理相关网站数据库(CFDA、FDA、Daily Med)和中国药品注册数据库等,了解当前利巴韦林的药品信息及临床应用现状;根据国内外利巴韦林的药品信息及报道的儿童临床应用情况,结合我院儿科临床应用的现状,对其安全性进行评价,促进其合理应用,并对中国利巴韦林制剂的规范化管理提出建议。
[Abstract]:Ribavirin is a synthetic nucleoside antiviral drug, which can inhibit the growth of respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus and so on in vitro. The mechanism of ribavirin is unclear. By searching Wanfang Medical Network, the Digital Library of Chinese Hospitals, the Medical knowledge Network, the website database of food and drug supervision and administration in China and the United States, CFDAF FDAU Daily Medand China Drug Registration Database, etc. To understand the current drug information and clinical application of ribavirin, to evaluate the safety of ribavirin according to the clinical application of ribavirin at home and abroad, combined with the present situation of pediatric clinical application in our hospital. To promote the rational application of ribavirin in China and put forward suggestions for standardized management of ribavirin preparation.
【作者单位】： 山西省儿童医院药剂科;山西医科大学药学院;
【基金】：国家卫生计生委药政司委托课题 山西省卫生厅科研课题资助项目(201301042)
【分类号】：R985
，

本文编号：2048040